Cipla Secures US FDA Approval for Generic Advair Diskus Inhaler

Clearance Unlocks Entry into $908 Million U.S. Respiratory Market

MUMBAI, India & WARREN, N.J. — Indian pharmaceutical company Cipla Limited, alongside its wholly owned subsidiary Cipla USA Inc., announced that it has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Generic Advair Diskus (fluticasone propionate and salmeterol inhalation powder).

The regulatory clearance covers all three therapeutic dosage strengths: 100/50 mcg, 250/50 mcg, and 500/50 mcg. The approved product is a therapeutically equivalent generic version of GSK’s Advair Diskus, a widely prescribed drug-device combination therapy indicated for the treatment of asthma and chronic obstructive pulmonary disease (COPD).

According to IQVIA market data, the addressable U.S. market for fluticasone propionate and salmeterol inhalation powder is estimated at approximately $908 million. Commercial launch in the United States is scheduled for the second quarter of fiscal year 2026–27.

First US-Based Dry Powder Inhaler Approval for Cipla

This milestone represents Cipla’s first dry powder inhaler (DPI) approval originating from its domestic U.S. manufacturing network located in New York. The development highlights the drugmaker's strategy to build complex, specialized drug-device combination capabilities directly inside North America.

Complex inhaled therapeutics carry steep regulatory and manufacturing entry barriers due to the need for precise device consistency and specialized bioequivalence studies. Securing FDA clearance strengthens Cipla's positioning in the high-value, low-competition complex generic respiratory category.

Official Regulatory Statements

According to official corporate disclosures submitted to regulatory authorities and stock exchanges:

"This approval reinforces our commitment to expanding access to complex therapies in the U.S. and highlights our strength in developing and scaling sophisticated inhalation products through integrated capabilities," stated Achin Gupta, Managing Director and Global CEO of Cipla Limited.

"This approval marks our first dry powder inhaler from our New York facility and reflects our targeted investments in building differentiated inhalation manufacturing capabilities in the U.S.," added Marc Falkin, Chief Executive Officer of Cipla North America.

Why It Matters

For patients, healthcare providers, and market participants, the arrival of an additional FDA-approved generic version of Advair Diskus provides direct practical benefits:

• Patient Access: Expands affordable, generic access to essential long-term maintenance treatments for asthma and COPD patients across North America.

• Supply Reliability: Localized production out of Cipla's New York site enhances supply chain stability for crucial drug-device respiratory combinations.

• Commercial Growth: Adds a high-margin, complex generic product to Cipla’s North American portfolio, aiding long-term revenue diversification.

Key Facts at a Glance

• Full Approval: Covers all three dosage strengths (100/50 mcg, 250/50 mcg, and 500/50 mcg).

• Market Potential: Targets an addressable U.S. market valued at roughly $908 million.

• New York Facility: Marks the firm’s first U.S. FDA dry powder inhaler approval manufactured at its domestic New York facility.

• Planned Commercialization: Scheduled to launch commercially in Q2 FY 2026–27.

Frequently Asked Questions (FAQs)

What conditions is Generic Advair Diskus approved to treat?

Generic Advair Diskus (fluticasone propionate and salmeterol inhalation powder) is approved for the long-term maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD).

Which strengths of Generic Advair Diskus were approved by the US FDA?

The U.S. FDA granted approval for all three commercial strengths: 100/50 mcg, 250/50 mcg, and 500/50 mcg.

Where will Cipla manufacture Generic Advair Diskus for the US market?

The product is manufactured using Cipla's vertically integrated respiratory platform at its U.S.-based manufacturing facility in New York.


Source: U.S. Food and Drug Administration (FDA), National Stock Exchange of India (NSE), BSE Limited